These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 29909237)

  • 1. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
    Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
    Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phostine 3.1a as a pharmacological compound with antiangiogenic properties against diseases with excess vascularization.
    Bousseau S; Marchand M; Soleti R; Vergori L; Hilairet G; Recoquillon S; Le Mao M; Gueguen N; Khiati S; Clarion L; Bakalara N; Martinez MC; Germain S; Lenaers G; Andriantsitohaina R
    FASEB J; 2019 May; 33(5):5864-5875. PubMed ID: 30817178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment.
    Croci DO; Cerliani JP; Pinto NA; Morosi LG; Rabinovich GA
    Glycobiology; 2014 Dec; 24(12):1283-90. PubMed ID: 25117007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism.
    Stapor P; Wang X; Goveia J; Moens S; Carmeliet P
    J Cell Sci; 2014 Oct; 127(Pt 20):4331-41. PubMed ID: 25179598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective.
    Missiaen R; Morales-Rodriguez F; Eelen G; Carmeliet P
    Vascul Pharmacol; 2017 Mar; 90():8-18. PubMed ID: 28082117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
    Croci DO; Cerliani JP; Dalotto-Moreno T; Méndez-Huergo SP; Mascanfroni ID; Dergan-Dylon S; Toscano MA; Caramelo JJ; García-Vallejo JJ; Ouyang J; Mesri EA; Junttila MR; Bais C; Shipp MA; Salatino M; Rabinovich GA
    Cell; 2014 Feb; 156(4):744-58. PubMed ID: 24529377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
    Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
    Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF signaling in cancer treatment.
    Sia D; Alsinet C; Newell P; Villanueva A
    Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
    Maes H; Olmeda D; Soengas MS; Agostinis P
    FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors.
    Indraccolo S
    Adv Exp Med Biol; 2013; 734():37-52. PubMed ID: 23143974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
    Simon T; Gagliano T; Giamas G
    Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting endothelial cell metabolism in cancerous microenvironment: a new approach for anti-angiogenic therapy.
    Mohammadi P; Yarani R; Rahimpour A; Ranjbarnejad F; Mendes Lopes de Melo J; Mansouri K
    Drug Metab Rev; 2022 Nov; 54(4):386-400. PubMed ID: 36031813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.